☀️     🌓

Prescribing Advice for GPs

An NHS Prescribing Advisers' Blog

Quadrivalent HPV protects against VaIN

The European Medicines Agency has recommended granting a license extension to the quadrivalent human papillomavirus (HPV) vaccine (Gardasil®).

This vaccine is already licensed for the prevention of high grade cervical dysplasia (CIN 2/3), high grade vulval dysplasia (VIN 2/3) and genital warts.

This extension will add prevention of high grade vaginal dysplasia (VaIN 2/3) to the indications for the vaccine. The Department of Health is due to announce which vaccine is to be used for the national HPV programme later this month but it would seem that there are distinct advantages to this vaccine over the bivalent alternative.

Action: Clinicians should be aware of the growing data to support HPV vaccination.

Share 'Quadrivalent HPV protects against VaIN' by emailShare 'Quadrivalent HPV protects against VaIN' on FacebookShare 'Quadrivalent HPV protects against VaIN' on TwitterShare 'Quadrivalent HPV protects against VaIN' on LinkedInShare 'Quadrivalent HPV protects against VaIN' on reddit


One Comment to “Quadrivalent HPV protects against VaIN”

  1. [...] previously noted, Gardasil® has a wider range of licensed indications based on the current Summaries of Product [...]

    Pingback by Prescribing Advice for GPs » HPV vaccine announced — June 19, 2008 #

Leave a Comment

Your email address will not be published. Required fields are marked *

Please be aware that you comment is subject to our Privacy Policy.

This site uses Akismet to reduce spam. Learn how your comment data is processed.

Prescribing Advice for GPs is powered by ClassicPress.
Connect to our RSS or Atom Feeds.